- PackSize
- 50ug/100ug
- Target
- CD268
- Reactivity
- Human
- Applications
- ELISA, Bioactivity: FACS, Functional assay, Research in vivo
- Host Species
- Human
- Isotype
- IgG1-kappa
- Conjugate/Modification
- --
- Recommended Dilution Ratio
- --
- Composition
- 0.01M PBS, pH 7.4.
- Purification Process
- Protein A/G purified from cell culture supernatant.
- Purity
- >95% purity as determined by SDS-PAGE.
- storageCondition
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
- Clonality
- Monoclonal
- Clone Number
- --
- Immunogen
- Mammalian Cells
- Alias
- BR3, TNFRSF13C, BAFF receptor, BLyS receptor 3, Tumor necrosis factor receptor superfamily member 13C, CD268, B-cell-activating factor receptor, BAFFR, BAFF-R
- Species
- --
- Gene ID-1
- Q96RJ3
- Uniprot
- --
- Background
- Ianalumab (VAY736) is an anti-B-cell activating factor (BAFF) receptor fully human IgG1 monoclonal antibody, engineered for direct ADCC-mediated B-cell depletion, thus providing a dual mode of action and targeted approach to treat pSS. The current phase 2b study aimed at establishing a dose-response relationship over a wide range of VAY736 doses, using change from baseline (BL) in the EULAR Sjogren’s Syndrome Disease Activity index (ESSDAI) over 24 Weeks (Wks) as the primary endpoint. Here we report Wk24 efficacy and safety. The study is ongoing with a second blinded treatment period up to Wk52.<br>• Soluble BAFF-R produced by decidual stromal cells plays an inhibitory role in monocytes and macrophages., PMID:22503273<br/>
- Tissue Expression
- --
- Signaling_pathway
- --
- Research Areas
- --